Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial.

BACKGROUND: Several clinical trials have assessed microbiota transplant therapy (MTT) in ulcerative colitis (UC); however, none have assessed a standardized MTT product. We developed a standardized, oral, lyophilized MTT product and previously reported the primary endpoint of engraftment at week 12. Here, we assessed clinical outcomes and the association with donor engraftment. METHODS: A single-center, randomized, double-blind, placebo-controlled pilot trial of patients with UC with an endoscopic Mayo score ≥1, who received MTT or placebo for 8 weeks. Symptom and fecal assessments occurred at baseline and weeks 4, 8, and 12. Secondary outcomes included the partial Mayo score (pMS) and correlation to donor engraftment. Stool microbiota were assessed via 16S rRNA sequencing and donor engraftment measured using SourceTracker. RESULTS: Participants receiving MTT (n = 13) had significantly higher donor engraftment at all measured time points compared with placebo (n = 14). Compared with baseline symptoms, participants who received MTT had significantly lower pMS at weeks 4 and 8, while no significant changes in pMS were noted in those randomized to placebo. There was no correlation between donor engraftment and pMS or clinical response. There was no significant pattern in engrafting donor taxa in those that met the threshold of clinical response at week 4 vs participants that did not meet clinical response. CONCLUSIONS: Daily dosing of encapsulated MTT for 8 weeks reduces symptoms of UC as measured by the pMS. However, donor engraftment did not correlate to pMS or clinical responses.NCT03948919, Fecal Transplant for Ulcerative Colitis, https://clinicaltrials.gov/study/NCT03948919.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-14
DOI
https://doi.org/10.1093/ibd/izag236
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial.

Byron P. Vaughn, Daphne Moutsoglou, Levi M. Teigen, Alexander Khoruts et al.
PubMed
Inflammatory Bowel Disease
article

Microbiota transplant therapy improves ulcerative colitis symptoms independent of donor engraftment in a pilot randomized placebo-controlled trial.

Byron P. Vaughn, Daphne Moutsoglou, Levi M. Teigen, Alexander Khoruts, William A. Nickols, Amanda J. Kabage, Dina C Belhasan, Monika Fischer, Christopher M. Staley, Sharon Lopez, Lulu Chen
article en

Abstract

BACKGROUND: Several clinical trials have assessed microbiota transplant therapy (MTT) in ulcerative colitis (UC); however, none have assessed a standardized MTT product. We developed a standardized, oral, lyophilized MTT product and previously reported the primary endpoint of engraftment at week 12. Here, we assessed clinical outcomes and the association with donor engraftment. METHODS: A single-center, randomized, double-blind, placebo-controlled pilot trial of patients with UC with an endoscopic Mayo score ≥1, who received MTT or placebo for 8 weeks. Symptom and fecal assessments occurred at baseline and weeks 4, 8, and 12. Secondary outcomes included the partial Mayo score (pMS) and correlation to donor engraftment. Stool microbiota were assessed via 16S rRNA sequencing and donor engraftment measured using SourceTracker. RESULTS: Participants receiving MTT (n = 13) had significantly higher donor engraftment at all measured time points compared with placebo (n = 14). Compared with baseline symptoms, participants who received MTT had significantly lower pMS at weeks 4 and 8, while no significant changes in pMS were noted in those randomized to placebo. There was no correlation between donor engraftment and pMS or clinical response. There was no significant pattern in engrafting donor taxa in those that met the threshold of clinical response at week 4 vs participants that did not meet clinical response. CONCLUSIONS: Daily dosing of encapsulated MTT for 8 weeks reduces symptoms of UC as measured by the pMS. However, donor engraftment did not correlate to pMS or clinical responses.NCT03948919, Fecal Transplant for Ulcerative Colitis, https://clinicaltrials.gov/study/NCT03948919.

PubMed
Indiana University Health (US), University of Minnesota (US), Harvard University (US), Minneapolis VA Health Care System (US)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon